Guggenheim Maintains Buy on Krystal Biotech, Raises Price Target to $130
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Debjit Chattopadhyay maintains a Buy rating on Krystal Biotech (NASDAQ:KRYS) and raises the price target from $101 to $130.
May 22, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst maintains Buy rating on Krystal Biotech and raises price target from $101 to $130.
The Guggenheim analyst's decision to maintain a Buy rating and raise the price target for Krystal Biotech indicates a positive outlook for the company's stock. This news is likely to have a positive impact on KRYS's stock price in the short term as it reflects increased confidence in the company's prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100